Endo’s Par Competes With Amneal On Sucralfate
Launches Authorized Generic Of Carafate Oral Suspension
Endo’s Par has partnered with Allergan to launch an authorized generic of Carafate sucralfate oral suspension in the US, competing directly with the first generic version recently launched by Amneal.
You may also be interested in...
After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.
Capitalizing on opportunities in the US hybrid 505(b)(2) market will be central to Amneal’s strategy to revive its fortunes now its founders, brothers Chirag and Chintu Patel, have again taken the helm.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.